甘草酸镁联合丁二磺酸腺苷蛋氨酸治疗药物性肝损伤患者疗效研究

doi:10.3969/j.issn.1672-5069.2021.02.021

Abstract

Abstract: Objective The aim of this study was to investigate the short-term efficacy of magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in treatment of patients with drug-induced liver injury (DILI) and serum heme monooxygenase 1(HO-1), nuclear factor E2 related factor 2(Nrf-2) and glutathione peroxidase (GSH-Px) level changes.Methods 78 patients with DILI were enrolled in this study between January 2018 and December 2019, and were randomly divided into control and combination groups, with 39 cases in each group. The patients in control group received intravenous infusion of adenosylmethionine butanedisulfonate, and those in the combination received intravenous infusion of magnesium isoglycyrrhizinate at the base of medicine in the control for two weeks. Serum Nrf-2, TNF-α, IL-10, NO, NOS, HO-1, GSH-Px and macrophage dectected.Results At the end two week migration inhibitory factor (MIF) were of treatment, serum alanine aminotransaminase level in the combination group was (65.9±7.7)U/L, serum AST level was (58.5±7.3)U/L, and serum total bilirubin level was (20.5±5.3)μmol/L, all significantly lower than 【(93.5±11.2)U/L, (91.3±10.8)U/L and (25.2±7.9)μmol/L, respectively, P<0.05】 in the control; serum NOS level was (47.7±5.8)U/mg, and serum GSH-Px level was (0.8±0.1)ng/mL, both significantly higher than 【(38.5±5.6)U/mg and (0.5±0.1)U/mg, respectively, P<0.05】, while serum HO-1 level was (0.4±0.1)ng/mL, and serum Nrf-2 level was (0.5±0.1)ng/mL, both significantly lower than 【(0.7±0.1)ng/mL and (0.8±0.1)U/mg, respectively, P<0.05】 in the control; serum TNF-α level was (3.0±0.5)ng/mL, and serum MIF level was (8.9±1.1)ng/mL, significantly lower than 【(4.2±0.6)ng/mL and (11.4±1.5)ng/mL, respectively, P<0.05】, while serum IL-10 level was (33.1±4.4)pg/mL, and serum NO level was (66.5±7.3)μmol/L, significantly higher than 【(22.5±2.9)pg/mL and (41.1±5.6)μmol/L, respectively, P<0.05】 in the control. Conclusion The magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in the treatment of patients with DILI have a short-term efficacy, which might be related to the inhibition of inflammatory and oxidative stress reactions, and needs further clinical investigation.

Key words: Drug-induced liver injury, Magnesium isoglycyrrhizinate, Adenosylmethionine butanedisulfonate, Heme monooxygenase 1, Nuclear factor E2 related factor 2, Glutathione peroxidase, Therapy

Lin Cheng, Wang Tongbiao, Li Yueyong, et al. Short-term efficacy of magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in treatment of patients with drug-induced liver injury[J]. Journal of Practical Hepatology, 2021, 24(2): 232-235.

References

[1] Yang ZB, Chen WW, Chen HP,et al. Mir-155 aggravated septic liver injury by oxidative stress-mediated er stress and mitochondrial dysfunction via targeting Nrf-2. Exp Mol Pathol, 2018, 105(3):387-394.
[2] Bessone F, Robles-Diaz M, Hernandez N,et al. Assessment of serious acute and chronic idiosyncratic drug-induced liver injury in clinical practice. Semin Liver Dis, 2019, 39(3):381-394.
[3] Grégoire S, Millecamps M, Naso L,et al. Therapeutic benefits of the methyl donor S-adenosylmethionine on nerve injury- induced mechanical hypersensitivity and cognitive impairment in mice. Pain, 2017, 158(5):802-810.
[4] Chen C, Liu YH, Cheng SB, et al. The hepatoprotective effects of XCHD and MgIG against methotrexate-induced liver injury and inflammation in rats through suppressing the activation of aim2 inflammasomes. Pathol Res Pract, 2020, 216(4):152875-152875.
[5] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南. 实用肝脏病杂志, 2017, 20(2):257-274.
[6] 中华医学会消化病学分会肝胆疾病协作组. 急性药物性肝损伤诊治建议(草案). 中华消化杂志, 2007, 27(11): 765-767.
[7] Teschke R. Top-ranking drugs out of 3312 drug-induced liver injury cases evaluated by the roussel uclaf causality assessment method. Expert Opin Drug Metab Toxicol, 2018, 14(11):1169-1187.
[8] Kleiner DE. Drug-induced liver injury:The hepatic pathologist's approach. Gastroenterol Clin North Am, 2017, 46(2):273-296.
[9] Xu Q, Wang J, Chen F,et al. Protective role of magnesium isoglycyrrhizinate in non-alcoholic fatty liver disease and the associated molecular mechanisms. Int J Mol Med, 2016, 38(1):275-282.
[10] Kim SH, Oh DS, Oh JY,et al. Silymarin prevents restraint stress-induced acute liver injury by ameliorating oxidative stress and reducing inflammatory response. Molecules, 2016, 21(4):443-443.
[11] Zou X, Wang Y, Peng C,et al. Magnesium isoglycyrrhizinate has hepatoprotective effects in an oxaliplatin induced model of liver injury. Int J Mol Med, 2018, 42(4):2020-2030.
[12] Howell LS, Ireland L, Park BK, et al. Mir-122 and other micrornas as potential circulating biomarkers of drug-induced liver injury. Expert Rev Mol Diagn, 2018, 18(1):47-54.
[13] 朱娅鸽, 刘锦峰. 丁二磺酸腺苷蛋氨酸联合复方甘草酸苷治疗酒精性肝硬化患者疗效及其对血清BGP水平的影响. 实用肝脏病杂志, 2019, 22(6): 872-875.
[14] Zhang W, Li F, Ye Y,et al. Isoglycyrrhizinate magnesium enhances hepatoprotective effect of FK506 on ischemia-reperfusion injury through HMGB1 inhibition in a rat model of liver transplantation. Transplantation, 2017, 101(12):2862-2872.
[15] Jiang W, Liu J, Li P,et al. Magnesium isoglycyrrhizinate shows hepatoprotective effects in a cyclophosphamide-induced model of hepatic injury. Oncotarget, 2017, 8(20):33252-33264.
[16] 樊沛, 鱼宁彬. 异甘草酸镁联合多烯磷酯酰胆碱治疗对慢性乙型肝炎患者血清细胞因子的影响和疗效观察. 实用肝脏病杂志, 2017, 20(3): 276-279.
[17] Zhou RJ, Ye H, Wang F,et al. Apigenin inhibits D-galactosamine/LPS-induced liver injury through upregulation of hepatic Nrf-2 and PPARγ expressions in mice. Biochem Biophys Res Commun, 2017, 493(1):625-630.
[18] Abdel-Gaber SA, Geddawy A, Moussa RA. The hepatoprotective effect of sitagliptin against hepatic ischemia reperfusion-induced injury in rats involvesNrf-2/HO-1 pathway. Pharmacol Rep, 2019, 71(6):1044-1049.
[19] Qu B, Xing R, Wang H,et al. Multiple effects of magnesium isoglycyrrhizinate on the disposition of docetaxel in docetaxel-induced liver injury. Xenobiotica, 2017, 47(4):290-296.
[20] Sui M, Jiang X, Chen J,et al. Magnesium isoglycyrrhizinate ameliorates liver fibrosis and hepatic stellate cell activation by regulating ferroptosis signaling pathway. Biomed Pharmacother, 2018, 106(1):125-133.
[21] Wang W, Li X, Xu J. Magnesium isoglycyrrhizinate attenuatesD-galactosamine/lipopolysaccharides induced acute liver injury of rat via regulation of the P38-MAPK and NF-κB signaling pathways. Immunopharmacol Immunotoxicol, 2018, 40(3):262-267.

Short-term efficacy of magnesium isoglycyrrhizinate and adenosylmethionine butanedisulfonate combination in treatment of patients with drug-induced liver injury

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Yuan Pingge, Chen Wenwen. Insights to new medicine development for treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 305-307.
[2]	Xu Wenting, Zhang Jihong, Wei Dongjue, et al. Efficacy of tenofovir rescue therapy for patients with chronic hepatitis B and rtM204 mutation [J]. Journal of Practical Hepatology, 2021, 24(3): 335-338.
[3]	Wang Xue, Qu Falin, Qi Weili, et al. Balance of peripheral blood Treg cells/ Th17 cells in patients with chronic hepatitis B and its impact on response to telbivudine treatment [J]. Journal of Practical Hepatology, 2021, 24(3): 339-342.
[4]	Qi Mei, Zhang Ruijin, Tian Shuping, et al. Impacting factors in response to immunosuppressive therapy in patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(3): 371-374.
[5]	Huang Chunyang, Chen Jie, Zhang Xiaodan, et al. Serum ALT/ALP ratio changes and histopathological features of patients with drug-induced liver injury acute hepatocellular type [J]. Journal of Practical Hepatology, 2021, 24(3): 379-382.
[6]	Wang Yunqiang, Wang Liping, Huang Dongmei, et al. Changes ofportal hemodynamics in patients with hepatitis B cirrhosis after transjugular intrahepatic portosystemic stent-shunt [J]. Journal of Practical Hepatology, 2021, 24(3): 399-402.
[7]	Wu Chang, Zhang Yuan’an, Peng Chunfen. Efficacy of endoscopic variceal ligation and carvedilol maintenance in the treatment of patients with liver cirrhosis and esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2021, 24(3): 403-406.
[8]	Zhao Kai, Xue Jinfeng, Xue Pengfei, et al. Application of Viatorr covered stent in TIPS for treatment of cirrhotics with portal hypertension [J]. Journal of Practical Hepatology, 2021, 24(3): 419-422.
[9]	Feng Hao, Lyu Haitao, Wang Ziwei, et al. Efficacy of one-step and step-by-steplaparoscopic cholecystectomy in the treatment of patients with gallbladder stones and common bile duct stones [J]. Journal of Practical Hepatology, 2021, 24(3): 435-438.
[10]	Zhang Xinhe, Tian Haoyu, Li Yiling. Current therapeutic strategy for patients with primary biliary cholangitis [J]. Journal of Practical Hepatology, 2021, 24(3): 453-456.
[11]	Guo Li, Song Yuanzong. Clinical management of pediatric patients with Alagille syndrome [J]. Journal of Practical Hepatology, 2021, 24(2): 160-163.
[12]	He Yufeng, Zhong Xiaoni, Huang Jianrong, et al. Short-term efficacy of tenofovir dipivoxil and entecavir in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2021, 24(2): 200-203.
[13]	Nie Liu, Peng Hanming, Liao Dongliang. Combination of ursodeoxycholic acid and prednisone and azathioprine in the treatment of patients with autoimmune hepatitis [J]. Journal of Practical Hepatology, 2021, 24(2): 224-227.
[14]	Liu Yunhua, Da Rongfeng, Xu Hubo, et al. Therapeutic efficacy of polyene phosphatidylcholine in patients with anti-tuberculosis agents-induced liver injury [J]. Journal of Practical Hepatology, 2021, 24(2): 228-231.
[15]	Zhang Yan, Xia Wenfang, Jin Jin, et al. Short-term observation ofglicladine and insulin aspart 50 in the treatment of patients with non-alcoholic fatty liver diseases and hepatogenic diabetes [J]. Journal of Practical Hepatology, 2021, 24(2): 240-243.